The strategic plan for the RMRCE is based on the program's past successes and those activities that have emerged as true and in many ways unique RMRCE strengths. These include: 1) establishment of nationally and internationally recognized expertise and research capabilities in understudied pathogens, especially Burkholderia and Coxiella;2) utilization of new BSL3 capabilities across the region, including the Rocky Mountain Regional Biocontainment Laboratory, 3) studies of only virulent Select Agents instead of model organisms;4) development of broad-platform technologies for therapeutics and vaccines;this includes cationic lipid DMA complex (CLDC) originally developed at Colorado State University which will be used by bacterial and viral research projects alike;5) highly integrated research projects;and 6) institution of region wide RMRCE leadership. These are the strengths and opportunities that the RMRCE will build on for the next 5 years. Additionally, the strategic plan takes into account NIAID mandated RCE activities that are in need of restructuring and refocusing under the RMRCE. Based on programmatic strengths the overall RMRCE structure (Figure 1) was developed to emphasize a robust and flexible research program that is directed at specific thematic areas important to the overall national effort in biodefense and emerging infectious diseases research, and that is supported by scientific cores designed to enhance research and facilitate product development. This structure and strategic plan also are aligned with the previously stated goals of this program. The details of the operation of the RMRCE and the individual components are described in the Action Plan (Section A-2.4) and the strengths and opportunities enabling this organizational structure are detailed in Sections A-2.1 and A-2.2. The thematic areas that from the basis of the RMRCE strategic plan are discussed in section A- 2.3.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54AI065357-08
Application #
8375724
Study Section
Special Emphasis Panel (ZAI1-DDS-M)
Project Start
Project End
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
8
Fiscal Year
2012
Total Cost
$564,825
Indirect Cost
$118,845
Name
Colorado State University-Fort Collins
Department
Type
DUNS #
785979618
City
Fort Collins
State
CO
Country
United States
Zip Code
80523
Skyberg, Jerod A; Lacey, Carolyn A (2017) Hematopoietic MyD88 and IL-18 are essential for IFN-?-dependent restriction of type A Francisella tularensis infection. J Leukoc Biol 102:1441-1450
Plumley, Brooke A; Martin, Kevin H; Borlee, Grace I et al. (2017) Thermoregulation of Biofilm Formation in Burkholderia pseudomallei Is Disrupted by Mutation of a Putative Diguanylate Cyclase. J Bacteriol 199:
Furuta, Yousuke; Komeno, Takashi; Nakamura, Takaaki (2017) Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci 93:449-463
Podnecky, Nicole L; Rhodes, Katherine A; Mima, Takehiko et al. (2017) Mechanisms of Resistance to Folate Pathway Inhibitors in Burkholderia pseudomallei: Deviation from the Norm. MBio 8:
Pettey, W B P; Carter, M E; Toth, D J A et al. (2017) Constructing Ebola transmission chains from West Africa and estimating model parameters using internet sources. Epidemiol Infect 145:1993-2002
Rhodes, Katherine A; Schweizer, Herbert P (2016) Antibiotic resistance in Burkholderia species. Drug Resist Updat 28:82-90
Lehman, Stephanie S; Mladinich, Katherine M; Boonyakanog, Angkana et al. (2016) Versatile nourseothricin and streptomycin/spectinomycin resistance gene cassettes and their use in chromosome integration vectors. J Microbiol Methods 129:8-13
Rico, Amber B; Phillips, Aaron T; Schountz, Tony et al. (2016) Venezuelan and western equine encephalitis virus E1 liposome antigen nucleic acid complexes protect mice from lethal challenge with multiple alphaviruses. Virology 499:30-39
Calvert, Amanda E; Dixon, Kandice L; Piper, Joseph et al. (2016) A humanized monoclonal antibody neutralizes yellow fever virus strain 17D-204 in vitro but does not protect a mouse model from disease. Antiviral Res 131:92-9
Westover, Jonna B; Sefing, Eric J; Bailey, Kevin W et al. (2016) Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses. Antiviral Res 126:62-8

Showing the most recent 10 out of 253 publications